MTOR and non-small cell lung carcinoma: Here, we have demonstrated the combinatorial efficacy of CDK4/6 and MEK inhibition in an in vivo model of KRAS-driven NSCLC and have demonstrated another possible mechanism for the synergy, as palbociclib treatment selects for cells that acquire MEK-ERK-mTOR dependence.